.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,822,490

« Back to Dashboard

Claims for Patent: 8,822,490

Title:Peripheral opioid receptor antagonists and uses thereof
Abstract: The present invention provides a compound of formula I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s): Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (East Hanover, NJ), Szeliga; Jan (Croton On Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:13/875,657
Patent Claims: 1. A packaged composition comprising a liquid composition comprising a compound of formula III: ##STR00031## wherein A.sup.- is a suitable anion; wherein the packaged composition is substantially free of tungsten; and wherein the liquid composition comprises less than about 190 ppm of a compound of formula II: ##STR00032## wherein X.sup.- is a suitable anion.

2. The packaged composition according to claim 1, wherein the liquid composition comprises less than about 190 ppm total of the compound of formula II and a compound of formula IV: ##STR00033## wherein: R.sup.1 and R.sup.2 are each independently C.sub.1-6 aliphatic; and X.sup.- is a suitable anion.

3. The packaged composition of claim 1, wherein the packaged composition comprises a syringe, a vial, a sachet or an ampoule.

4. A packaged composition comprising a liquid composition comprising a compound of formula III-1: ##STR00034## wherein the liquid composition comprises less than about 190 ppm of a compound of formula II-1: ##STR00035##

5. The packaged composition of claim 4, wherein the packaged composition comprises a syringe, a vial, a sachet or an ampoule.

6. The packaged composition according to claim 4, comprising less than about 190 ppm total of the compound of formula II-1 and a compound of formula IV-1: ##STR00036##

7. The packaged composition according to claim 1, comprising 8 mg of a compound of formula III-1: ##STR00037## in 0.4 mL water, and a compound of formula II-1: ##STR00038## wherein the compound of formula II-1 is present in an amount of less than about 190 ppm.

8. The packaged composition according to claim 7, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.

9. The packaged composition according to claim 1, comprising 12 mg of a compound of formula III-1: ##STR00039## in 0.6 mL water, and a compound of formula II-1: ##STR00040## wherein the compound of formula II-1 is present in an amount of less than about 190 ppm.

10. The packaged composition according to claim 9, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.

11. A method comprising the steps of: (i) providing a packaged composition, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of a compound of formula III-1: ##STR00041## in 0.4 mL or 0.6 mL water, and a compound of formula II-1: ##STR00042## wherein the compound of formula II-1 is present in an amount of less than about 190 ppm; and (ii) administering the unit dosage to a subject via subcutaneous injection.

12. The method of claim 11, wherein the packaged composition comprises a syringe, a vial, a sachet or an ampoule.

13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.

14. The method according to claim 11, wherein the tungsten is present in an amount of less than 50 parts per billion.

15. The method according to claim 11, wherein the tungsten is present in an amount of less than 12 parts per billion.

16. The method according to claim 11, wherein the liquid composition further comprises edetate calcium disodium and glycine hydrochloride.

17. The packaged composition of any one of claims 4-6, wherein the packaged composition is substantially free of tungsten.

18. The packaged composition of claim 1, wherein the liquid composition comprises less than about 187 ppm of the compound of formula II.

19. The packaged composition of claim 2, wherein the liquid composition comprises less than about 187 ppm total of the compound of formula II and the compound of formula IV.

20. The packaged composition of claim 4, wherein the liquid composition comprises less than about 187 ppm of the compound of formula II-1.

21. The packaged composition of claim 6, comprising less than about 187 ppm total of the compound of formula II-1 and the compound of formula IV-1.

22. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 187 ppm.

23. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 187 ppm.

24. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 187 ppm.

25. The packaged composition of claim 1 or 4, wherein the packaged composition comprises a syringe.

26. The method of claim 11, wherein the packaged composition comprises a syringe.

27. The packaged composition of claim 1, wherein the liquid composition comprises less than about 185 ppm of the compound of formula II.

28. The packaged composition of claim 1, wherein the liquid composition comprises less than about 150 ppm of the compound of formula II.

29. The packaged composition of claim 1, wherein the liquid composition comprises less than about 125 ppm of the compound of formula II.

30. The packaged composition of claim 1, wherein the liquid composition comprises less than about 100 ppm of the compound of formula II.

31. The packaged composition of claim 1, wherein the liquid composition comprises less than about 25 ppm of the compound of formula II.

32. The packaged composition of claim 2, wherein the liquid composition comprises less than about 185 ppm total of the compound of formula II and the compound of formula IV.

33. The packaged composition of claim 2, wherein the liquid composition comprises less than about 150 ppm total of the compound of formula II and the compound of formula IV.

34. The packaged composition of claim 2, wherein the liquid composition comprises less than about 125 ppm total of the compound of formula II and the compound of formula IV.

35. The packaged composition of claim 2, wherein the liquid composition comprises less than about 100 ppm total of the compound of formula II and the compound of formula IV.

36. The packaged composition of claim 2, wherein the liquid composition comprises less than about 25 ppm total of the compound of formula II and the compound of formula IV.

37. The packaged composition of claim 4, wherein the liquid composition comprises less than about 185 ppm of the compound of formula II-1.

38. The packaged composition of claim 4, wherein the liquid composition comprises less than about 150 ppm of the compound of formula II-1.

39. The packaged composition of claim 4, wherein the liquid composition comprises less than about 125 ppm of the compound of formula II-1.

40. The packaged composition of claim 4, wherein the liquid composition comprises less than about 100 ppm of the compound of formula II-1.

41. The packaged composition of claim 4, wherein the liquid composition comprises less than about 25 ppm of the compound of formula II-1.

42. The packaged composition of claim 6, comprising less than about 185 ppm total of the compound of formula II-1 and the compound of formula IV-1.

43. The packaged composition of claim 6, comprising less than about 150 ppm total of the compound of formula II-1 and the compound of formula IV-1.

44. The packaged composition of claim 6, comprising less than about 125 ppm total of the compound of formula II-1 and the compound of formula IV-1.

45. The packaged composition of claim 6, comprising less than about 100 ppm total of the compound of formula II-1 and the compound of formula IV-1.

46. The packaged composition of claim 6, comprising less than about 25 ppm total of the compound of formula II-1 and the compound of formula IV-1.

47. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 185 ppm.

48. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 150 ppm.

49. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 125 ppm.

50. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 100 ppm.

51. The packaged composition of claim 7, wherein the compound of formula II-1 is present in an amount of less than about 25 ppm.

52. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 185 ppm.

53. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 150 ppm.

54. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 125 ppm.

55. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 100 ppm.

56. The packaged composition of claim 9, wherein the compound of formula II-1 is present in an amount of less than about 25 ppm.

57. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 185 ppm.

58. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 150 ppm.

59. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 125 ppm.

60. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 100 ppm.

61. The method of claim 11, wherein the compound of formula II-1 is present in an amount of less than about 25 ppm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc